세계의 레드 바이오테크놀러지 시장 - 산업 규모, 점유율, 동향, 경쟁, 기회, 예측 : 제품 유형별, 용도별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)

Red Biotechnology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Product Type, By Application, By End-User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,279,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,674,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,163,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 레드 바이오테크놀러지 시장은 2024년 4,213억 2,000만 달러로 평가되었고, 2030년에는 7,741억 5,000만 달러에 달하며, 예측 기간 동안 CAGR은 10.67%를 나타낼 것으로 전망됩니다.

시장 개척의 원동력이 되고 있는 것은 유전자 공학의 진보, 생명을 위협하는 질환을 타겟으로 한 신규 치료제에의 요구의 높아짐, 정밀의료 개발의 급증입니다. 치료 및 진단 용도를 위한 생체세포 및 생체분자 프로세스의 사용이 포함됩니다. 맞춤형 치료와 질병 특이적 치료 수요가 계속 확대되고 있는 가운데, 레드 바이오테크놀러지 부문은 선진국 시장과 신흥국 시장의 양쪽에서 큰 성장을 이루는 위치에 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모(2024년)	4,213억 2,000만 달러
시장 규모(2030년)	7,741억 5,000만 달러
CAGR(2025-2030년)	10.67%
급성장 부문	유전자 변형 의약품
최대 시장	북미

시장 성장 촉진요인

만성 및 희귀질환 관리에서 바이오 의약품 수요 증가

주요 시장 과제

높은 개발 비용과 복잡한 규제 요건

주요 시장 동향

맞춤형 의료 및 유전체학 기반 치료 확대

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 레드 바이오테크놀러지 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 제품 유형(진단 시약, 인체 백신, 혈액 제제, 유전자 재조합 의약품 등)
  • 용도별(바이오의약품 제조, 유전자 치료, 유전자 검사, 약물유전체학, 신약 개발 등)
  • 최종 사용자별(제약 및 바이오테크놀러지 기업, CMO·CRO, 조사 기관 등)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 아시아태평양의 레드 바이오테크놀러지 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국.
  • 인도.
  • 한국
  • 일본
  • 호주

제7장 유럽의 레드 바이오테크놀러지 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 북미의 레드 바이오테크놀러지 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제9장 남미의 레드 바이오테크놀러지 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 레드 바이오테크놀러지 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 합병과 인수
• 제품 개발

제13장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 협상력
• 고객의 협상력
• 대체품의 위협/서비스

제14장 세계의 레드 바이오테크놀러지 시장 : SWOT 분석

제15장 경쟁 구도

• Pfizer, Inc.
• Takeda Pharmaceutical Company Limited
• Gilead Sciences
• Regeneron Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• Bruker Corporation
• Merck KGaA
• Celgene Corporation
• Amgen Inc.
• Biogen Inc.

제16장 전략적 제안

제17장 기업 소개와 면책사항

KTH

영문 목차

영문목차

The Global Red Biotechnology Market was valued at USD 421.32 billion in 2024 and is projected to reach USD 774.15 billion by 2030, growing at a CAGR of 10.67% during the forecast period. Market growth is being driven by increasing advancements in genetic engineering, the growing need for novel therapeutics targeting life-threatening diseases, and the surge in precision medicine development. Red biotechnology involves the use of living cells and biomolecular processes for therapeutic and diagnostic applications, including the production of vaccines, gene therapies, diagnostic reagents, and biopharmaceuticals. As demand for personalized treatments and disease-specific therapies continues to expand, the red biotechnology sector is positioned for significant growth across both developed and emerging markets.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 421.32 Billion
Market Size 2030	USD 774.15 Billion
CAGR 2025-2030	10.67%
Fastest Growing Segment	Gene Recombinant Drugs
Largest Market	North America

Key Market Drivers

Rising Demand for Biopharmaceuticals in Chronic and Rare Disease Management

The increasing prevalence of chronic and rare diseases is a major factor accelerating the demand for red biotechnology, especially in the development of biopharmaceuticals such as recombinant proteins, monoclonal antibodies, and gene therapies. These innovations are addressing unmet medical needs where traditional treatments fall short. According to the World Health Organization (WHO), chronic illnesses-including cancer, cardiovascular diseases, diabetes, and respiratory disorders-account for approximately 74% of all global deaths. In parallel, rare diseases impact over 300 million individuals worldwide. Red biotechnology plays a vital role in the development of precision therapies for these complex health conditions, driving investment and research in this field globally.

Key Market Challenges

High Development Costs and Complex Regulatory Requirements

A major challenge in the red biotechnology market is the substantial cost and complexity associated with developing advanced therapeutics such as gene therapies and biologics. The R&D process involves extensive clinical trials, strict regulatory compliance, and rigorous quality controls, often resulting in long timelines and high expenses. According to the U.S. Congressional Budget Office (CBO), the cost of developing a single biopharmaceutical product can exceed $2.6 billion, and innovations within red biotechnology frequently surpass this due to their technical intricacies. Regulatory bodies such as the FDA and EMA impose detailed requirements for safety, efficacy, and long-term monitoring, particularly for gene-editing therapies. The variability in regulatory frameworks across different countries adds further challenges to global product launches, impacting speed to market and operational efficiency.

Key Market Trends

Expansion of Personalized Medicine and Genomics-Based Therapies

A transformative trend in the red biotechnology market is the rapid advancement of personalized medicine and genomics-driven therapies. Personalized medicine involves tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors. Red biotechnology is central to this trend through the development of targeted therapies, gene-editing tools, and molecular diagnostics. The widespread adoption of next-generation sequencing (NGS) and genomic profiling has enabled deeper understanding of disease mechanisms, supporting the creation of patient-specific treatment plans. The declining cost of genome sequencing-from nearly $100 million in 2001 to under $1,000 in 2024-has accelerated clinical integration of genomics, propelling growth in red biotechnology applications.

Key Market Players

• Pfizer, Inc.
• Takeda Pharmaceutical Company Limited
• Gilead Sciences
• Regeneron Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• Bruker Corporation
• Merck KGaA
• Celgene Corporation
• Amgen Inc.
• Biogen Inc.

Report Scope:

In this report, the Global Red Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Red Biotechnology Market, By Product Type:

• Diagnostic Reagents
• Human Vaccines
• Blood Products
• Gene Recombinant Drugs
• Others

Red Biotechnology Market, By Application:

• Biopharmaceutical Production
• Gene Therapy
• Genetic Testing
• Pharmacogenomics
• Drug Discovery
• Others

Red Biotechnology Market, By End-User:

• Pharmaceutical and Biotechnology Companies
• CMO & CRO
• Research Institute
• Others

Red Biotechnology Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Red Biotechnology Market.

Available Customizations:

Global Red Biotechnology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered.
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Red Biotechnology Market Outlook.

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Diagnostic Reagents, Human Vaccines, Blood Products, Gene Recombinant Drugs and Others)
  • 5.2.2. By Application (Biopharmaceutical Production, Gene Therapy, Genetic Testing, Pharmacogenomics, Drug Discovery, and Others)
  • 5.2.3. By End-User (Pharmaceutical and Biotechnology companies, CMO & CRO, Research Institute and Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. Asia-Pacific Red Biotechnology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Asia-Pacific: Country Analysis
  • 6.3.1. China Red Biotechnology Market Outlook.
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-User
  • 6.3.2. India Red Biotechnology Market Outlook.
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-User
  • 6.3.3. South Korea Red Biotechnology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-User
  • 6.3.4. Japan Red Biotechnology Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By End-User
  • 6.3.5. Australia Red Biotechnology Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By End-User

7. Europe Red Biotechnology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Red Biotechnology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-User
  • 7.3.2. Germany Red Biotechnology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Red Biotechnology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Red Biotechnology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Red Biotechnology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-User

8. North America Red Biotechnology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Red Biotechnology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-User
  • 8.3.2. Mexico Red Biotechnology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-User
  • 8.3.3. Canada Red Biotechnology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-User

9. South America Red Biotechnology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Red Biotechnology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Red Biotechnology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Red Biotechnology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Red Biotechnology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Red Biotechnology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Red Biotechnology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Red Biotechnology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products/Services

14. Global Red Biotechnology Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Pfizer, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Takeda Pharmaceutical Company Limited
• 15.3. Gilead Sciences
• 15.4. Regeneron Pharmaceuticals, Inc.
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. Bruker Corporation
• 15.7. Merck KGaA
• 15.8. Celgene Corporation
• 15.9. Amgen Inc.
• 15.10. Biogen Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료